article thumbnail

PharmaShots Weekly Snapshot (August 20-24, 2018)

PharmaShots

Eisai's and Merck Announces EU's Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular Carcinoma Published: 23 Aug,2018 | Tags: Eisai, Merck, Approval, Lenvima, HCC, 2. Pfizer to co-promote Exact Sciences Cologuard Published: 22 Aug,2018 | Tags: Exact, Pfizer, Agreement, Promote, Cologuard 7.

article thumbnail

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

Even before the Covid pandemic, a 2018 paper reported that new genetic tests, many of them for increasingly rare conditions, were being released at the rate of 10 a day. You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s.

Labelling 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Include penicillin allergy history in medicines reconciliation to ensure accurate status, says RPS

Hospital Pharmacy Europe

They should then ensure that records are updated for any patients with a penicillin allergy label that have since successfully received penicillin without an allergic reaction. Mislabelled penicillin allergy Figures show around 6% of people have a penicillin allergy label on their medical record, equating to four million people in the UK.

article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

in revenue across seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan) in 2018, and also was the first approved biologic therapy for LN in the US, having gained approval in 2020. in 2018 across the 7MM despite being an off-label therapy for lupus.

Labelling 111
article thumbnail

OTC asthma inhaler pros and cons

The Checkup by Singlecare

Primatene Mist was actually taken off the market in 2011 due to CFC use and not reintroduced until 2018 in the HFA form. It is approved and labeled for use in patients 12 and older who have been previously diagnosed with asthma. Healthcare providers occasionally administer these products off-label for croup at even younger ages.

article thumbnail

The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sick | Editorial

The Guardian - Pharmaceutical Industry

Then came Orkambi in 2015 and Symkevi in 2018 – both two-drug combinations. Kaftrio is the latest to be labelled unaffordable for a cash-strapped NHS. The drugs that have caused such a stir are made by the US biotech company Vertex. Since 2020, there has been Kaftrio, which is a triple combination. Continue reading.

article thumbnail

UK medical cannabis manufacturer granted GMP registration

European Pharmaceutical Review

The first good manufacturing practice (GMP) registration of a UK pharmaceutical facility for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API) has been granted since the legalisation of medical cannabis in 2018. The firm’s medicinal cannabis product will be supplied in oil form as an API.